ArticleBlood2014
Functional factor XIII-A is exposed on the stimulated platelet surface.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 118 citations in OpenAlex.
- Whole blood storage time impairs clot strength with minimal change in functional fibrinogen concentration.Transfusion · 2026Article
- Personalised viscoelastometry-guided systemic thrombolysis for high- and intermediate-high-risk acute pulmonary embolism in the ICU: a single-centre randomised controlled interventional feasibility trial.Intensive care medicine experimental · 2026Article
- Factor XIII Deficiency: A Review of Biology, Testing, and Treatment.Clinical hematology international · 2026Review
- Review
- Transcription factor RUNX1 regulates coagulation factor XIII-A (Research and practice in thrombosis and haemostasis · 2025Article
- Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation.Blood advances · 2024Article
- Fluorescent peptide for detecting factor XIIIa activity and fibrin in whole blood clots forming under flow.Research and practice in thrombosis and haemostasis · 2024Article
- Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability.Research and practice in thrombosis and haemostasis · 2023Article
- Transglutaminase Activities of Blood Coagulant Factor XIII Are Dependent on the Activation Pathways and on the Substrates.Thrombosis and haemostasis · 2023Article
- All tangled up: interactions of the fibrinolytic and innate immune systems.Frontiers in medicine · 2023Review
- Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases.International journal of molecular sciences · 2022Review
- Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1.International journal of molecular sciences · 2022Article
- Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.Arteriosclerosis, thrombosis, and vascular biology · 2022Review
- Ethacrynic acid is an inhibitor of human factor XIIIa.BMC pharmacology & toxicology · 2022Article
- Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications.International journal of molecular sciences · 2022Review
- The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells.International journal of molecular sciences · 2022Article
- Another piece of knowledge in the puzzle of procoagulant COAT platelets.Journal of thrombosis and haemostasis : JTH · 2022Article
- Activation mechanism dependent surface exposure of cellular factor XIII on activated platelets and platelet microparticles.Journal of thrombosis and haemostasis : JTH · 2022Article
- Factor XIII is a newly identified binding partner for platelet collagen receptor GPVI-dimer-An interaction that may modulate fibrin crosslinking.Research and practice in thrombosis and haemostasis · 2022Article
- Mechanisms Underlying Dichotomous Procoagulant COAT Platelet Generation-A Conceptual Review Summarizing Current Knowledge.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Factor XIII (FXIII) stabilizes thrombi against fibrinolysis by cross-linking α2-antiplasmin (α2AP) to fibrin. Cellular FXIII (FXIII-A) is abundant in platelets, but the extracellular functions of this pool are unclear because it is not released by classical secretion mechanisms. We examined the function of platelet FXIII-A using Chandler model thrombi formed from FXIII-depleted plasma. Platelets stabilized FXIII-depleted thrombi in a transglutaminase-dependent manner. FXIII-A activity on activated platelets was unstable and was rapidly lost over 1 hour. Inhibiting platelet activation abrogated the ability of platelets to stabilize thrombi. Incorporating a neutralizing antibody to α2AP into FXIII-depleted thrombi revealed that the stabilizing effect of platelet FXIII-A on lysis was α2AP dependent. Platelet FXIII-A activity and antigen were associated with the cytoplasm and membrane fraction of unstimulated platelets, and these fractions were functional in stabilizing FXIII-depleted thrombi against lysis. Fluorescence confocal microscopy and flow cytometry revealed exposure of FXIII-A on activated membranes, with maximal signal detected with thrombin and collagen stimulation. FXIII-A was evident in protruding caps on the surface of phosphatidylserine-positive platelets. Our data show a functional role for platelet FXIII-A through exposure on the activated platelet membrane where it exerts antifibrinolytic function by cross-linking α2AP to fibrin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.